ProKidney Corp. (PROK)

NASDAQ: PROK · IEX Real-Time Price · USD
2.350
-0.050 (-2.08%)
At close: Jul 12, 2024, 4:00 PM
2.420
+0.070 (2.98%)
After-hours: Jul 12, 2024, 6:54 PM EDT
-2.08%
Market Cap 670.74M
Revenue (ttm) n/a
Net Income (ttm) -35.30M
Shares Out 285.42M
EPS (ttm) -0.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 367,881
Open 2.490
Previous Close 2.400
Day's Range 2.300 - 2.520
52-Week Range 1.120 - 13.510
Beta 1.31
Analysts Buy
Price Target 7.25 (+208.51%)
Earnings Date Aug 8, 2024

About PROK

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidne... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 163
Stock Exchange NASDAQ
Ticker Symbol PROK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for PROK stock is "Buy." The 12-month stock price forecast is $7.25, which is an increase of 208.51% from the latest price.

Price Target
$7.25
(208.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

4 weeks ago - GlobeNewsWire

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

4 weeks ago - GlobeNewsWire

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) --  ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD...

4 weeks ago - GlobeNewsWire

ProKidney to Participate in the Jefferies Global Healthcare Conference

WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD),...

6 weeks ago - GlobeNewsWire

ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024

WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidn...

7 weeks ago - GlobeNewsWire

ProKidney Reports Business Updates and First Quarter 2024 Financial Results

WINSTON-SALEM, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidn...

2 months ago - GlobeNewsWire

ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies

3 months ago - GlobeNewsWire

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic ki...

4 months ago - GlobeNewsWire

ProKidney to Participate in Jefferies Biotech on the Bay Summit

WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD)...

4 months ago - GlobeNewsWire

ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer

Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKid...

8 months ago - GlobeNewsWire

ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference

WINSTON-SALEM, N.C, Nov. 21, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving k...

8 months ago - GlobeNewsWire

ProKidney Reports Third Quarter Financial Results

WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD)...

8 months ago - GlobeNewsWire

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients

8 months ago - GlobeNewsWire

ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023

Total of 6 abstracts accepted for publication in Kidney Week 2023 program Total of 6 abstracts accepted for publication in Kidney Week 2023 program

9 months ago - GlobeNewsWire

ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference

WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving...

11 months ago - GlobeNewsWire

ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights

WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-fr...

1 year ago - GlobeNewsWire

ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC

WINSTON-SALEM, N.C., July 18, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving ...

1 year ago - GlobeNewsWire

ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

- Brings more than 20 years of academic and industry experience with extensive  expertise in kidney disease - WINSTON-SALEM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“Pr...

1 year ago - GlobeNewsWire

ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC

WINSTON-SALEM, N.C., June 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving ...

1 year ago - GlobeNewsWire

ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference

WINSTON-SALEM, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

1 year ago - GlobeNewsWire

ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights

WINSTON-SALEM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidn...

1 year ago - GlobeNewsWire

ProKidney to Present at the BofA Securities Health Care Conference 2023

WINSTON-SALEM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD),...

1 year ago - GlobeNewsWire

ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights

WINSTON-SALEM, N.C., March 28, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic ki...

1 year ago - GlobeNewsWire

ProKidney to Participate in TD Cowen's 43rd Annual Health Care Conference

WINSTON-SALEM, N.C., March 03, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD...

1 year ago - GlobeNewsWire

ProKidney's stock jumps 29%

Shares of ProKidney Corp. PROK, +9.57% rallied about 29% in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the company's investigationa...

1 year ago - Market Watch